- Home
- CRSP vs STEP Comparison
CRSP vs STEP Comparison
Compare CRSP & STEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- STEP
- Stock Information
- Founded
- CRSP 2013
- STEP 2007
- Country
- CRSP Switzerland
- STEP United States
- Employees
- CRSP N/A
- STEP N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- STEP Finance/Investors Services
- Sector
- CRSP Health Care
- STEP Finance
- Exchange
- CRSP Nasdaq
- STEP Nasdaq
- Market Cap
- CRSP 4.9B
- STEP 4.6B
- IPO Year
- CRSP 2016
- STEP 2020
- Fundamental
- Price
- CRSP $57.68
- STEP $60.69
- Analyst Decision
- CRSP Buy
- STEP Buy
- Analyst Count
- CRSP 16
- STEP 7
- Target Price
- CRSP $70.73
- STEP $63.43
- AVG Volume (30 Days)
- CRSP 3.7M
- STEP 530.8K
- Earning Date
- CRSP 08-04-2025
- STEP 08-07-2025
- Dividend Yield
- CRSP N/A
- STEP 2.24%
- EPS Growth
- CRSP N/A
- STEP N/A
- EPS
- CRSP N/A
- STEP N/A
- Revenue
- CRSP $37,675,000.00
- STEP $1,174,830,000.00
- Revenue This Year
- CRSP $28.31
- STEP N/A
- Revenue Next Year
- CRSP $268.05
- STEP $25.11
- P/E Ratio
- CRSP N/A
- STEP N/A
- Revenue Growth
- CRSP N/A
- STEP 65.09
- 52 Week Low
- CRSP $30.04
- STEP $40.07
- 52 Week High
- CRSP $71.13
- STEP $70.38
- Technical
- Relative Strength Index (RSI)
- CRSP 52.32
- STEP 56.55
- Support Level
- CRSP $61.13
- STEP $60.55
- Resistance Level
- CRSP $69.58
- STEP $62.31
- Average True Range (ATR)
- CRSP 3.89
- STEP 1.57
- MACD
- CRSP -0.71
- STEP -0.12
- Stochastic Oscillator
- CRSP 28.46
- STEP 41.38
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.